METHODS: We collected the blood samples of septic patients and measured the relative expression of serum miR-155 by RT-qPCR, and drew the receiver operating characteristic (ROC) curves to evaluate its early diagnosis for septic AKI.
RESULTS: The relative expression of miR-155 in the septic AKI was significantly higher than that in the septic non-AKI, and increased with the aggravation of renal function damage. The ROC curve of miR-155 for the diagnosis of septic AKI was 1.91 (95% CI: 1.61-2.19). When the optimal cut-off value of miR-155 expression was 2.37, its sensitivity for diagnosing septic AKI was 91.12% (95% CI: 80.41-95.07%), and its specificity was 84.52% (95% CI: 71.74-89.36%). Furthermore, the severity of kidney injury, SOFA score, APACHE II score and miR-155 were the risk factors affecting the prognosis of septic patients with AKI.
CONCLUSIONS: Serum miR-155 can be used as a novel biomarker for the early diagnosis of septic AKI, and also has important clinical value in the prognosis evaluation of septic patients with AKI.
方法:我们收集脓毒症患者的血样,通过RT-qPCR检测血清miR-155的相对表达,并绘制受试者工作特征(ROC)曲线,以评估其对感染性AKI的早期诊断。
结果:脓毒症AKI中miR-155的相对表达量明显高于非脓毒症AKI。并随着肾功能损害的加重而加重。miR-155诊断脓毒症AKI的ROC曲线为1.91(95%CI:1.61-2.19)。当miR-155表达的最佳截断值为2.37时,其诊断感染性AKI的敏感性为91.12%(95%CI:80.41-95.07%),特异性为84.52%(95%CI:71.74-89.36%)。此外,肾损伤的严重程度,SOFA得分,APACHEⅡ评分和miR-155是影响脓毒症AKI患者预后的危险因素。
结论:血清miR-155可作为感染性AKI早期诊断的新生物标志物。对脓毒症合并AKI患者的预后评估也具有重要的临床价值。